Metformin-Derived Hybrid Molecules for Glioblastoma Treatment by Delehedde, Caroline et al.
HAL Id: hal-02393327
https://hal-amu.archives-ouvertes.fr/hal-02393327
Submitted on 5 Dec 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Distributed under a Creative Commons Attribution| 4.0 International License
Metformin-Derived Hybrid Molecules for Glioblastoma
Treatment
Caroline Delehedde, Mathieu Chocry, Sophie Thétiot-Laurent, Françoise
Garrouste, Marcel Culcasi, Hervé Kovacic, Sylvia Pietri
To cite this version:
Caroline Delehedde, Mathieu Chocry, Sophie Thétiot-Laurent, Françoise Garrouste, Marcel Culcasi,
et al.. Metformin-Derived Hybrid Molecules for Glioblastoma Treatment. Proceedings, MDPI, 2019,
22 (1), pp.83. ￿10.3390/proceedings2019022083￿. ￿hal-02393327￿
  
Proceedings 2019, 22, 83; doi:10.3390/proceedings2019022083 www.mdpi.com/journal/proceedings 
Abstract 
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Glioblastoma is the most common cerebral tumor in adults. The median survival of glioblastoma 
patients is 12 months. Metformin is a biguanide used as a standard clinical drug for the treatment of 
type 2 diabetes. Recently, several studies revealed that the risk of cancer development was 
significantly reduced for diabetic patients treated with metformin compared to those treated with 
insulin or sulfonylureas [1]. Even if metformin acts as an antitumoral agent, it is a nontoxic molecule 
with IC50 around 10 mM in cancer cells. In cancer research, naturally occurring phenolic acids are 
well known to be useful antioxidant agents and allow the inhibition of the migration and adhesion 
of cancer cells [2]. Moreover, a recent study [3] on nitrones combined with phenolic acids has shown 
that phenolic acids keep their antioxidant properties even if they are coupled with another molecule. 
The purpose of this study is to design new molecules combining metformin and a phenolic acid to 
improve the cytotoxicity on cancer cells. 
A series of hybrid molecules was then synthesized. For each molecule, IC50 on glioblastoma cell 
lines (U87 and U251) and on human dermal fibroblasts was tested. After this first screening, the 
mechanisms through which the best hybrid molecules act on cancer cells were studied and compared 
with those of metformin. Finally, the study of cytotoxicity on cancer stems cells of glioblastoma, 
GBM6, and GBM9 revealed that metformin-derived molecules may also restrict the growth of stem 
cells. As cancer stem cells are one of the causes of tumor resistance [4], metformin hybrid molecules 
may become a novel therapeutic option to treat glioblastoma. 
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